Stockreport

Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy [Seeking Alpha]

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF Looking ahead, their GAlette Phase 2a trial is enrolling, which could further validate the rest of their portfolio's potential. LCTX's pipeline also has OPC1 for spin [Read more]